Skip to main content

Table 1 Echocardiographic data in post-MI rats.

From: Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

 

Timepoint

Sham Operated

(N = 10)

Vehicle Control

(N = 13)

GLPL

(N = 11)

GLPH

(N = 11)

3174L

(N = 11)

3174H

(N = 7)

LVEDD (cm)

Baseline

0.63 ± 0.01

0.93 ± 0.02*

0.89 ± 0.01*

0.88 ± 0.02*

0.86 ± 0.02*

0.85 ± 0.04*

 

End of Study

0.82 ± 0.01†

1.16 ± 0.02

1.04 ± 0.03†

1.03 ± 0.03†

1.07 ± 0.03†

0.98 ± 0.05†

LVESD (cm)

Baseline

0.34 ± 0.01

0.77 ± 0.02*

0.73 ± 0.02*

0.71 ± 0.02*

0.70 ± 0.03*

0.70 ± 0.03*

 

End of Study

0.05 ± 0.01†

0.99 ± 0.03

0.85 ± 0.03†

0.82 ± 0.04†

0.89 ± 0.04

0.73 ± 0.06†

FS (%)

Baseline

46 ± 2

17 ± 1*

18 ± 1*

19 ± 1*

18 ± 2*

18 ± 1*

 

End of Study

39 ± 1†

16 ± 1

20 ± 2

21 ± 2†

18 ± 1†

26 ± 3†

LVEDV (ml)

Baseline

0.26 ± 0.02

0.59 ± 0.03*

0.52 ± 0.03*

0.53 ± 0.03*

0.56 ± 0.04*

0.52 ± 0.05*

 

End of Study

0.51 ± 0.02†

0.99 ± 0.05

0.83 ± 0.05†

0.72 ± 0.04†

0.77 ± 0.02†

0.73 ± 0.06†

LVESV (ml)

Baseline

0.08 ± 0.01

0.37 ± 0.03*

0.32 ± 0.02*

0.33 ± 0.03*

0.34 ± 0.03*

0.33 ± 0.04*

 

End of Study

0.17 ± 0.01†

0.69 ± 0.04

0.52 ± 0.05†

0.42 ± 0.04†

0.47 ± 0.03†

0.44 ± 0.07†

LVEF (%)

Baseline

69 ± 2

37 ± 2*

39 ± 1*

39 ± 2*

39 ± 3*

38 ± 3*

 

End of Study

66 ± 2†

31 ± 2

38 ± 3†

43 ± 3†

39 ± 3†

41 ± 5†

E Wave (cm/s)

End of Study

0.89 ± 0.04

1.05 ± 0.50

0.93 ± 0.07

0.89 ± 0.05

1.02 ± 0.06

0.95 ± 0.04

A Wave (cm/s)

End of Study

0.48 ± 0.06†

0.36 ± 0.06

0.42 ± 0.04†

0.43 ± 0.04†

0.45 ± 0.05†

0.44 ± 0.05†

E/A Ratio

Baseline

1.6 ± 0.1

3.4 ± 0.5*

4.4 ± 0.8*

3.9 ± 0.6*

3.9 ± 0.8*

4.0 ± 0.4*

 

End of Study

2.0 ± 0.2†

4.5 ± 0.8

2.5 ± 0.4†

2.5 ± 0.4†

2.9 ± 0.6†

2.5 ± 0.5†

E Wave Deceleration (m/s 2 )

Baseline

13.8 ± 0.6

18.5 ± 1.2*

19.2 ± 1.8*

17.7 ± 0.8*

17.9 ± 1.4*

18.0 ± 0.6*

 

End of Study

16 ± 1†

25 ± 3

18 ± 3†

16 ± 2†

19 ± 3

17 ± 2†

LV Wall Thinning Ratio

Baseline

1.06 ± 0.02

0.87 ± 0.02*

0.89 ± 0.03*

0.89 ± 0.02*

0.89 ± 0.03*

0.88 ± 0.03*

 

End of Study

1.08 ± 0.03†

0.76 ± 0.02

0.84 ± 0.04

0.88 ± 0.04†

0.79 ± 0.04

0.93 ± 0.06†

Heart Rate (beats/min)

Baseline

273 ± 5

270 ± 7

266 ± 10

292 ± 10

284 ± 7

261 ± 2

 

End of Study

257 ± 15

243 ± 7

269 ± 8

262 ± 6

246 ± 9

258 ± 7

CO/Body Wt (ml/min/g)

End of Study

0.21 ± 0.01†

0.17 ± 0.01

0.20 ± 0.01†

0.20 ± 0.01†

0.19 ± 0.01†

0.22 ± 0.01†

  1. The LV wall thinning ratio is the ratio of the anterior wall thickness to the posterior wall thickness. Mean ± SEM. *P < 0.05 versus sham-operated group at baseline. †P < 0.05 versus vehicle-treated group at the end of the study. LV, left ventricular; EDD, end-diastolic dimension; ESD, end-systolic dimension; FS, fractional shortening; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; E, early filling wave; A, late filling wave; E/A ratio, Doppler ratio of early to late transmitral flow velocity; Wt, weight; CO, cardiac output.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840